Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma

Yanfang Wang; Zhenhao Zhang; Lingli Wang; Hua Wang; Fei Dong

doi:10.1016/j.cancergen.2024.03.004

Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma

Cancer Genet. 2024 Mar 12:284-285:12-15. doi: 10.1016/j.cancergen.2024.03.004. Online ahead of print.

Authors

Yanfang Wang¹, Zhenhao Zhang¹, Lingli Wang¹, Hua Wang¹, Fei Dong²

Affiliations

¹ Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
² Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China. Electronic address: knowflying7979@163.com.

PMID: 38493578
DOI: 10.1016/j.cancergen.2024.03.004

Abstract

Background: Therapy-related acute myeloid leukemia (t-AML) is increasingly recognized as a treatment complication in patients receiving chemotherapy, radiotherapy, or immunosuppressive agents for primary neoplasms. NUP98::PRRX1 fusion gene, caused by t(1;11)(q23;p15), is a rare recurrent cytogenetic alteration in leukemia, and only seven cases with NUP98::PRRX1 were reported so far.

Methods: A 53-year-old female patient was diagnosed with t-AML after 20 months of complete remission (CR) from diffuse large B-cell lymphoma (DLBCL). Conventional karyotype, fluorescence in situ hybridization (FISH), and DNA/RNA next-generation sequence (NGS) were used to detect genetic abnormalities.

Results: Abnormal karyotype of 46, XX, t(1;11)(q25;p15), del(7)(q22) was revealed. NUP98 gene rearrangement and del(7)(q22) were verified by FISH. Further, RNA NGS detected NUP98::PRRX1 fusion transcript, and DNA NGS detected KRAS gene mutation. The patient achieved CR after a combined chemotherapy regimen containing BCL-2 inhibitor and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), but she died of leukemia recurrence 14 months later.

Conclusions: Novel targeted drugs may provide opportunities for patients with NUP98::PRRX1 to undergo allo-HSCT. However, since the cases of carrying the NUP98::PRRX1 are limited, more patients with this genetic change need to be investigated to elucidate the prognostic significance.

Keywords: 7q Deletion; Cytotoxic drug; NUP98; NUP98::PRRX1; Therapy-related acute myeloid leukemia.